In February 2012, a new venture was launched Doing Business As (DBA) Leaders in Pharmaceutical Business Intelligence. Founder & Director of Pharmaceutical Business Intelligence Services is Aviva Lev-Ari, PhD, RN.
The venture operates as an online scientific intellectual EXCHANGE — an Open Access Online Scientific Journal for curation and reporting on frontiers in Biomedical, Genomics, Biological Sciences, Healthcare Economics, Pharmacology, Pharmaceutical & Medicine. The website, http://pharmaceuticalintelligence.com , is a scientific, medical and business multi expert authoring environment in several domains of LIFE SCIENCES, PHARMACEUTICAL, HEALTHCARE & MEDICINE INDUSTRIES.
|Author Name||Total Views
4/2012 to 7/2015
|# of Articles|
|Aviva Lev-Ari, PhD, RN||207,592||2,004|
|Larry H Bernstein, MD, FCAP||114,265||620|
|Tilda Barliya, PhD||32,651||46|
|Stephen J Williams, PhD||20,508||77|
|Dror Nir, PhD||17,372||53|
|Sudipta Saha, PhD||16,301||58|
|Ritu Saxena, PhD||12,664||40|
|Demet Sag, PhD||7,160||24|
|Aviral Vatsa, PhD||6,922||20|
|Anamika Sarhar, PhD||2,901||7|
|Prabod Kandala, PhD||1,998||43|
|Alan F Kaul, PharmD, FCCP||1,730||4|
|Asshir Awan, PhD||1,366||4|
|Meg Baker, PhD||1,266||4|
|Justin D Pearlman, MD, PhD, FACC||773||3|
VIEW VIDEO on Open Access Exaplained!
Published on Oct 25, 2012
What is open access? Nick Shockey and Jonathan Eisen take us through the world of open access publishing and explain just what it’s all about. Make sure to watch it in HD and Fullscreen!
Animation by Jorge Cham
Narration by Nick Shockey and Jonathan Eisen
Transcription by Noel Dilworth
Produced in partnership with the Right to Research Coalition, the Scholarly Publishing and Resources Coalition and the National Association of Graduate-Professional Students
Creative Commons Attribution license (reuse allowed)
THUS, our articles follows the Creative Commons Attribution
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See:http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode.
We are carving a new niche for ourselves on the spectrum that lies between Open Scientific Journals and On-Line Scientific Publishing. We have a better business model as we offer the public at large & to our own Scientific Team of Experts, Authors, Writers (EAW) the following advantages:
– Interdisciplinary work. scientific work from different domains is published on one site with over-arching domains serving as Parent Categories (PC). In our case, all PCs are within the Life Sciences, Pharmaceutical, Healthcare & Medicine.
– Collaborative authoring platform. Collaboration with other scientists around the globe is fostered on the web. Comments and Ratings by other Scientists are equally valuable to peer review.
– Multiple writing categories for post categorization. Several categories of research are on one site, facilitating the process applied by a Scientist to classify his/hers post in several categories at once for RESEARCH REFERENCING purposes.
– Increasing VISIBILITY of each Scientist in the SCIENTIFIC COMMUNITY by our OWN Research Category System (RCS) which supplements the Search Engines TAGGING system – represents a double reinforced CLASSIFICATION offering. Thus, achieving a higher fidelity and higher RELEVANCE of each subject matter SEARCH conducted on the Web.
– Increasing VISIBILITY of our Scientific Web Site (SWS) – We represent a NEW ORGANIZATIONAL TYPE of virtual MANAGEMENT and performance of SCIENTIFIC WORK! Each of the 65 Research Categories has a Category OWNER (CO). The Scientist in this role is an Expert on the subject matter, charts the research agenda of the Research Category and COMMISSIONS other Experts, Author, Writers to feature POSTS of great importance, subjectively judged as such. Thanks to their original thinking, the entire SWS is been improved.
In 2013 and Beyond, we are launching a Series of e-Books (electronic Books) in BioMedicine.
Series Editor-in-Chief, Aviva Lev-Ari, PhD, RN has created over 300 article in an inventory of 735 available on March 13, 2013 on http://pharmaceuticalintelligence.com. The BioMedicine e- Book Series is planning the publication of the following e-Books:
Perspectives on Nitric Oxide in Disease Mechanisms (2013), Larry Bernstein, MD, FCAP and Aviral Vatsa, PhD, Editors
Target Market: CARDIOLOGISTS
Cardiovascular Diseases Causes, Risks and Management (2013) Juston D. Pearlman, MD, PhD, Editor Target Market: CARDIOLOGISTS
Genomics in Disease Diagnosis (2013) SJ Williams, PhD, A. Lev-Ari, PhD, RN and Larry H. Bernstein, MD, FCAP, Editors
Target Market: Life Scientists and BIG PARMA, Academia and the Public
Metabolic Genomics & Pharmaceutics (2013), Larry Bernstein, MD, FCAP & Ritu Saxena, PhD, Editors
Target Market: GI MDs, Nutritionists, Food Industry, Academia and the Public
Cancer Biology and Genomics for Disease Diagnosis,
S.J.Williams, PhD, Sr. Editor, Tilda Barliya, PhD, Ritu Saxena, PhD: Editors
Target Market: ONCOLOGISTS
Nanotechnology in Drug Delivery, Tilda Barliya, PhD, Editor
Target Market: BIG PHARMA & Academics
Thanks to the organization and content of the website, the time from Lab/Desk to access online Publication on the Internet and all Search Engines Optimization (SEO) is reduced to seconds.
Growth of the Equity Sharing Venture: The venture is ramping up fast to 25 Scientists, publishing in tandem and simultaneously growing our Research Categories System (RCS).
On August 22, 2012, 65 LIVE categories were accessed 24×7 around the Globe with >16,000 views.
On October 24, 2012, 69 LIVE categories were accessed 24×7 around the Globe with >46,500 views.
On November 24, 2012, 73 LIVE categories were accessed 24×7 around the Globe with >63,390 views.
On February 11, 2013, 85 LIVE categories were accessed 24×7 around the Globe with >115,000 views.
On September 11, 2013, 101 LIVE categories were accessed 24×7 around the Globe with >238,937 views.
On December 4, 2013, 151 LIVE categories were accessed 24×7 around the Globe with >289,688 views.
Recruitment to the Scientific Team: Joining The EAW Team is an iterative process. After joining, EAW’s life would never be the same. Elite Scholars, PhDs, MDs, MD/PhDs, PharmD, and Technical MBA from top 5 GSB, are emerging into an enhanced version of their EAW persona as a result of the team collaboration, Esprit de Corps, Research Leadership and the Network of Contacts in the industry of Applied Research institutions.
Dr. Lev-Ari, a University of California, BERKELEY, PhD ’83, has served as Director at SRI International in the mid 80s, Head of Research at MITRE in the mid 90s, and the Director of Research at McGraw-Hill in the early of the first decade of the 21st Century. Dr. Lev-Ari is the leader behind the venture and is presently involved in candidate selection of potential new EAW. She qualifies their application by reviewing their writing samples, credentials and list of publications. Overseeing the work of the Scientists is done in the following ways: She reads EVERY Post, rates it and comments on it first. She then invites certain other EAWs to comment on specific Posts. Dr. Lev-Ari commissions daily EAWs to author/curate/write/report on research topics chosen from multiple electronic feeds reaching her from multiple Global Sources.
INCREASED VISIBILITY and continuous attraction of Scholars for a Re-Pub Program called Bibliographies of Note was launched in July 2012, has the potential to make http://pharmaceuticalintelligence.com – the next KEY OPINION LEADER (KOL) for scientific critique and exposition of the FRONTIER OF SCIENCE applying our interdisciplinary training in Life Sciences, Pharmaceutical, Healthcare & Medicine.
The Dynamic List of our Research Categories System (RCS) for scientific information integration and conceptual critical analysis include:
- Genomic Medicine Research
- Bone disease
- Chemical Genetics
- Cell Biology and Cell Circuits
- Computational Biology and Bioinformatics
- Medical and Population Genetics
- Genome Biology
- Chemical Biology and its relations to Metabolic Disease
- Infectious Disease discovering new antibiotic targets for
- Biological networks, gene regulation and evolution.
- Disease biology, using small molecules toward the development of therapeutic drugs.
- Cardiovascular Pharmaceutical Genomics
- Health Economics and Outcomes Research
- Pharmaceutical Analytics
- Pharmaceutical Industry Competitive Intelligence
- Pharmacotherapy of Cardiovascular Disease
- Population Health Management, Genetics & Pharmaceutical
- HealthCare IT
- International Global Work in Pharmaceutical
- Pharmaceutical R&D Investment
- Innovations in Cancer Therapy
- Bio Instrumentation in Experimental Life Sciences Research
- Reproductive Biology & Bio Instrumentation
- Innovations in Neurophysiology & Neuropsychology
- Molecular Cardiology & Cardiovascular Disease
- Innovations in Cardiac & Vascular Procedures & Medical Devices
- Clinical Trials & IRB
- Biomarkers and medical diagnostics
- Bio Instrumentation in Experimental Life Sciences Research
- FDA Regulatory Affairs
- Alzheimer’s Disease
- Bone Disease and Musculoskeletal Disease
- Nanotechnology for Drug Delivery
- Population Health Management, Nutrition and Phytochemistry
- Reproductive Biology and Bio Instrumentation
- Systemic Inflammatory Response Related Disorders
- Statistical Methods for Research Evaluation
- Nitric Oxide in Health and Disease
- Imaging-based Cancer Patient Management
- Glycobiology: Biopharmaceutical Production, Pharmacodynamics and Pharmacokinetics
- Health Law & Patient Safety
Aviva Lev-Ari, PhD, RN
TRIBUTE & INSPIRATION
Part I, II, III of my research on Cardiovascular Disease was an inspiration to launch a Scientific Web Site where I can present that material among other Life Scientists working on a collaborative authoring system.
I wish to thank my past Professors who contributed to my knowledge in the Life Sciences and for enabling me to embark on a new line of creative research in pharmaco-therapy for cardiovascular disease (CVD).
Anatomy and Physiology professors, Prof. Amy Walsh, Biology Department, Northeastern University, for teaching the superfamilies of extra cellularly activated ligand-gated ion channel subunits. Prof. Eugene Bernstein, Pharmaceutical Sciences, Bouve College of Health Sciences, Northeastern University, for reiterating the importance of the endothelium, endothelin, the roles of Nitric Oxide, and for his passion for the physiology of the Heart which succeeded “to move my own heart” and research interests towards the cardiovascular field. Prof. Edward Cosgrove, Biology Department, Northeastern University, for being a gifted teacher that has inspired me to get interested in Microbiology, Immunology and Genetics. Due to his superb explanations, I was able to study these three new fields expeditiously. Prof. Connie Calvin, Pathophysiology Professor, School of Nursing, Northeastern University. I thank her for sharing with the students medical cases she had encountered in Anesthesia, and for sharing with us cutting edge research on cancer and CVD. Prof. Valeria Ramdin, School of Nursing, Northeastern University, taught Foundations of Nursing with patient advocacy in mind, a gifted teacher and a superb role model in Nursing education. With the content I learned from them, I courageously initiated and researched the topics covered in Part I.
Chemistry Prof. Chris Toher, Chemistry Department, Northeastern University. I gained much from his inspirational teaching style and I thank him for offering important guidance to me all along. With what I learned in his four classes I dared to step into the domains covered in Part II.
Pharmacology Prof. Paul Abourjaily, Bouve College of Health Sciences, Northeastern University, for my new exposure into Pharmacology and Pharmaco-therapy, a new field I discovered and became intrigued to join. With what he has taught me I researched and wrote Part I, II, and III. Without attending his most inspiring Advanced Pharmacology graduate class in Spring 2006, I could not have even contemplated on the scientific domains I subsequently researched in Part I, II, and III. Most likely, these three parts would not have been written at all, by myself, or by any other scholar. Vascular biologists seldom acquire the thought process of pharmacologists. While the later do venture into cell biology, neither the first, nor the second community, does venture into the interdisciplinary domain codified in algorithm design as developed in Part III while being entirely derived from the content in Part I and II.
Dr. J. Walker, Cardiac Surgeon at MGH, Dr. I. Palacios, Director Catheterization Lab, MGH, Mr. D. Rosenthal, Chief PA, Interventional Radiology, Cardiovascular Diagnostic and Intervention Center, BWH and Ms. S. Lieberman, Coronary ICU, BWH–I thank them all for allowing me to shadow their work in the Operating Room and Angiography suites, an experience which further solidified my interest in cardiovascular disease.
The late, Prof. Louis Guttman who’s student I was in Measurement Theory in 1974-1976, and with his teachings I launched a twenty-year career of creative applied research in Analytics Design. I transferred his teachings into Part III of this project. Prof. Allan Pred, my doctoral advisor at UC, Berkeley, for his unmatched demonstration of the intellectual power of a creative scholar. Prof. Marcus Feldman, Biological Sciences, Stanford University, for sharing the passion for research design and innovative advanced statistical analysis, since my years at Stanford Research Institute (SRI Int’l), Menlo Park, CA in the mid 80s.
Prof. P.G. Abir-Am, Life Sciences Scholar and Science Writer, Belmont, MA. Her writings on the history and philosophy of the Life Sciences, in particular, Molecular Biology, were inspirational for many years, till in 2005, I joined this fast growing field, as a student.
Prof. H. Lev-Ari, EE Department, Northeastern University, who watched my academic growth since 1970. For his support and deep theoretical and technical understanding of the challenges involved in starting a research track in a new field while attempting to integrate the new with the very familiar, as done in Part III.